Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Earnings for Prothena Corporation plc (PRTA)
Earnings in 2023 (TTM): $-160,480,000
According to Prothena Corporation plc's latest financial reports the company's current earnings (TTM) are $-160,480,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Prothena Corporation plc
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-160,480,000 | $-147,028,000 |
| 2022 | $-125,605,000 | $-116,949,000 |
| 2021 | $71.92 M | $66.98 M |
| 2020 | $-111,427,000 | $-111,144,000 |
| 2019 | $-77,298,000 | $-77,677,000 |
| 2018 | $-156,115,000 | $-155,645,000 |
| 2017 | $-157,603,000 | $-153,237,000 |
| 2016 | $-158,964,000 | $-160,108,000 |
| 2015 | $-79,911,000 | $-80,612,000 |
| 2014 | $-6,339,000 | $-7,150,000 |
| 2013 | $-40,581,000 | $-40,996,000 |
| 2012 | $-41,405,000 | $-41,411,000 |
| 2011 | $-29,244,000 | $-29,670,000 |
| 2010 | $-12,162,000 | $-12,482,000 |